Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Operating Margin (2020 - 2025)

Ovid Therapeutics filings provide 6 years of Operating Margin readings, the most recent being 1712.12% for Q4 2025.

  • Quarterly Operating Margin rose 1239578.0% to 1712.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 670.25% through Mar 2026, up 973395.0% year-over-year, with the annual reading at 585.2% for FY2025, 1034854.0% up from the prior year.
  • Operating Margin hit 1712.12% in Q4 2025 for Ovid Therapeutics, up from 9487.12% in the prior quarter.
  • Across five years, Operating Margin topped out at 84.73% in Q1 2021 and bottomed at 115329.27% in Q3 2022.
  • Average Operating Margin over 5 years is 17203.38%, with a median of 11402.01% recorded in 2023.
  • Peak annual rise in Operating Margin hit 10429349bps in 2023, while the deepest fall reached -2075618bps in 2023.
  • Ovid Therapeutics' Operating Margin stood at 84.73% in 2021, then tumbled by -31144bps to 26302.75% in 2022, then surged by 51bps to 12808.45% in 2023, then fell by -10bps to 14107.89% in 2024, then surged by 88bps to 1712.12% in 2025.
  • Per Business Quant, the three most recent readings for OVID's Operating Margin are 1712.12% (Q4 2025), 9487.12% (Q3 2025), and 80.88% (Q2 2025).